MedPacto, Inc. researches and develops anti-cancer drugs. It engages in the development of therapeutic products to cure ulcer or neuropathy caused by diabetes. The company was founded by Seong-Jin Kim on June 19, 2013 and is headquartered in Seoul, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company